Genevant Sciences and Arbutus Biopharma File Patent Infringement Action Against Moderna | Your money
Conference call today at 8:00 a.m. ET
VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28. 10, 2022 (GLOBE NEWSWIRE) — Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the United States District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and an affiliate claiming damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651 and 11,141,378 in the manufacture and sale of mRNA-1273, Moderna’s vaccine against COVID-19. The patents relate to lipid-nucleic acid particles and lipid vesicles, as well as compositions and methods for their use. The complaint filed is available at https://investor.roivant.com/news-events/events.
Genevant and Arbutus are not seeking an injunction or otherwise to restrain the sale, manufacture or distribution of mRNA-1273. Genevant is collaborating with various companies and non-profit organizations to develop COVID-19 vaccines in territories around the world, including low- and middle-income countries, with the goal of eradicating COVID-19.
It is well established in the scientific literature that the most significant technological hurdle to the development and deployment of drugs using mRNA is the design of a safe and effective way to deliver mRNA to human cells. Arbutus and Genevant scientists have spent years developing and refining lipid nanoparticle (LNP) delivery technology, which has been licensed for various applications to many different third parties. Genevant and Arbutus’ LNP technology relies on microscopic particles made up of four carefully selected types of fatty molecules to house and protect RNA molecules. Using this technology, RNA can travel through the human body to a target cell and through the target cell membrane before releasing RNA. Without this crucial delivery technology, RNA would rapidly degrade in the body and be ineffective.
In December 2021, the United States Court of Appeals for the Federal Circuit denied Moderna’s appeal against an earlier decision by the United States Patent Trial and Appeal Board stating that all claims of the ‘069 patent claims were patentable and dismissed Moderna’s appeal challenging a similar finding of patentability with respect to certain claims of the claimed ‘435 patent. Moderna had launched inter partes review (IPR) challenges against these patents in 2018 and 2019.
Genevant will participate in a live conference call and webcast today at 8:00 a.m. ET hosted by Roivant Sciences (Nasdaq: ROIV), the principal shareholder of Genevant. To access the live conference call, please dial +1 (844) 224-1923 (domestic) or +1 (214) 989-7105 (international) and use conference ID 1379815. A link to the broadcast Web will be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website following the conference call.
About Genevant Sciences Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a broad and strong lipid nanoparticle (LNP) patent estate and decades of experience and expertise in the delivery and development of nucleic acid drugs. The Company’s scientists have pioneered LNP nucleic acid delivery for more than 20 years, and the Company’s LNP platform, which has been studied on more than a dozen discrete product candidates and is the technology of delivery behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide range of RNA-based applications, including vaccines, production of therapeutic proteins and gene editing. For more information, please visit www.genevant.com.
Pete Zorn Geneva Sciences firstname.lastname@example.org
Copyright 2022 GlobeNewswire, Inc.